AstraZeneca (LON:AZN) Stock Price Expected to Rise, Berenberg Bank Analyst Says

AstraZeneca (LON:AZN) had its price objective lifted by stock analysts at Berenberg Bank from £145 to £160 in a research report issued to clients and investors on Tuesday, Marketbeat reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Berenberg Bank’s price objective points to a potential upside of 18.45% from the company’s current price.

A number of other analysts have also recently commented on the stock. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research note on Friday, January 16th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Citigroup started coverage on AstraZeneca in a research note on Tuesday. They set a “buy” rating and a £170 price objective for the company. Deutsche Bank Aktiengesellschaft increased their target price on AstraZeneca from £105 to £110 and gave the company a “sell” rating in a report on Thursday, January 15th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a £150 price target on shares of AstraZeneca in a research note on Monday, November 10th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of £145.83.

AstraZeneca Price Performance

AstraZeneca stock opened at £135.08 on Tuesday. The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. The company’s fifty day moving average price is £137.66 and its 200 day moving average price is £125.59. The stock has a market capitalization of £209.41 billion, a P/E ratio of 22.44, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a 1 year low of GBX 9,573.51 and a 1 year high of £144.10.

Insider Buying and Selling at AstraZeneca

In related news, insider Nazneen Rahman sold 297 shares of the stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of £134.96, for a total value of £40,083.12. 0.14% of the stock is currently owned by corporate insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.